Eden Research PLC (AIM:EDEN, OTCQB:EDNSF) CEO Sean Smith talked with Proactive's Stephen Gunnion about recent developments, including the company's growth and new regulatory achievements.
Smith highlighted the second consecutive approval for Ecovelex in Italy, an important product in their bio-pesticide lineup. He emphasised that while regulatory processes are challenging and costly, they are also crucial for expanding Eden's market reach. He stated, "Regulatory is a double-edged sword... it creates opportunities."
Smith also discussed the company's trading update, with revenue forecast to increase 34% for 2024 £4.3 million, reaching £5 million in 2025 due to US regulatory timings. The CEO mentioned that the company's strategic efforts are aimed at sustaining growth through new product launches and regulatory gains, despite timing challenges.